Repligen EPS - Earnings per Share 2010-2024 | RGEN

Repligen earnings per share (EPS) for the twelve months ending December 31, 2024 was $-0.46, a 173.02% decline year-over-year.

  • Repligen EPS for the quarter ending December 31, 2024 was $-0.61, a 110.34% increase year-over-year.
  • Repligen 2024 annual EPS was $-0.46, a 173.02% decline from 2023.
  • Repligen 2023 annual EPS was $0.63, a 80.56% decline from 2022.
  • Repligen 2022 annual EPS was $3.24, a 44.64% increase from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.

Repligen EPS - Earnings per Share 2010-2024 | RGEN

  • Repligen EPS for the quarter ending December 31, 2024 was $-0.61, a 110.34% increase year-over-year.
  • Repligen 2024 annual EPS was $-0.46, a 173.02% decline from 2023.
  • Repligen 2023 annual EPS was $0.63, a 80.56% decline from 2022.
  • Repligen 2022 annual EPS was $3.24, a 44.64% increase from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$209.6B
Amgen (AMGN)$149.1B
Gilead Sciences (GILD)$130.2B
Vertex Pharmaceuticals (VRTX)$125.6B
Bristol Myers Squibb (BMY)$100.2B
CSL (CSLLY)$74.3B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$61.6B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$30.5B
BioNTech SE (BNTX)$23.7B
BeiGene (ONC)$22.8B
Biogen (BIIB)$17.4B
Genmab (GMAB)$13.3B
Genmab (GNMSF)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.3B
Illumina (ILMN)$11.3B
Incyte (INCY)$11.3B
Ascendis Pharma (ASND)$10.1B
Exelixis (EXEL)$10B
Swedish Orphan Biovitrum (BIOVF)$9.6B
Moderna (MRNA)$9.6B
QIAGEN (QGEN)$9B
Exact Sciences (EXAS)$7.7B
Bio-Techne Corp (TECH)$7.6B
Halozyme Therapeutics (HALO)$7.3B
Roivant Sciences (ROIV)$7.2B
Revolution Medicines (RVMD)$6.8B
Bio-Rad Laboratories (BIO.B)$6.3B